Management of hypertension emergencies

Current Hypertension Reports

Volumn 5, Issue 6, 2003, Pages 486-492

  Elliott, William J ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CATECHOLAMINE DERIVATIVE; CLONIDINE; COCAINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; FELODIPINE; FENOLDOPAM MESILATE; GLYCERYL TRINITRATE; GUANABENZ; GUANFACINE; HYDRALAZINE; LABETALOL; MAGNESIUM SULFATE; METHYLDOPA; MONOAMINE OXIDASE INHIBITOR; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NITROPRUSSIDE SODIUM; PHENCYCLIDINE; PHENTOLAMINE; UNINDEXED DRUG; URAPIDIL; VASODILATOR AGENT;

AMBLYOPIA; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; BRAIN FUNCTION; CARDIOVASCULAR RISK; DIURESIS; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; EMERGENCY MEDICINE; FLUSHING; HEADACHE; HEART DISEASE; HEART FUNCTION; HUMAN; HYPERTENSIVE CRISIS; HYPOTENSION; INCIDENCE; INTENSIVE CARE UNIT; INTRAOCULAR HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; LEBER HEREDITARY OPTIC NEUROPATHY; MALIGNANT HYPERTENSION; MATERNAL HYPERTENSION; NEUROLOGICAL COMPLICATION; ORGAN INJURY; PATHOPHYSIOLOGY; PREGNANCY; PROGNOSIS; REVIEW; RISK FACTOR; TACHYCARDIA; VASCULAR DISEASE;

EID: 3142622987     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-003-0056-3     Document Type: Review

References (50)

1. Chobanian AV, Bakris GL, Black HR, et al.: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). JAMA, 2003, 289: 2560-2572.
2. Gifford RW Jr: Management of hypertensive crises. JAMA 1991, 266:829-835.
3. Kaplan NM: Management of hypertensive emergencies. Lancet 1994, 344:1335-1338.
4. Varon J, Marik PE: The diagnosis and management of hypertensive crises. Chest 2000, 118:214-227.
5. Elliott WJ: Hypertensive emergencies. Crit Care Clin 2001, 17:435-451.
6. Elliott WJ: Hypertensive urgencies. In The Kidney and Hypertension. Edited by Bakris GL. London: Martin Dunitz Publishers; 2003, In press.
7. Ahmed MEK, Walker JM, Beevers DG, Beevers M: Lack of difference between malignant and accelerated hypertension. BMJ 1986, 292:235-237.
8. Lip GYH, Beevers M, Beevers DG: Complications and survival in 315 patients with malignant-phase hypertension. J Hypertens 1995, 13:915-924.
9. Keith NM, Wagener HP, Kernohan JW: The syndrome of malignant hypertension. Arch Intern Med 1928, 41:141-153.
10. Felmeden DC, Beevers DG, Yip GYH: Tackling malignant hypertension: not so desperate now [letter]. Am Heart J 2002, 144:E4.
11. Kumar P, Arora P, Kher V, et al.: Malignant hypertension in children in India. Nephrol Dial Transplant 1996, 11:1261-1266.
12. De Lima JJ, da Fonseca JA, Godoy A, et al.: Outcome of patients with malignant hypertension and end-stage renal failure treated by long-term hemodialysis. Cardiology 1999, 92:93-98.
13. Kadiri S, Olutade BO, Osobamiro O: Factors influencing the development of malignant hypertension in Nigeria. J Hum Hypertens 2000, 14:171-174.
14. Kadiri S, Thomas JO: Focal segmental glomerulosclerosis in malignant hypertension. S Afr Med J 2002, 92:303-305.
15. Sung JF, Harris-Hooker S, Alema-Mensah E, Mayberry R: Is there a difference in hypertensive claim rates among Medicaid recipients? Ethn Dis 1997, 7:19-26.
16. Shea S, Misra D, Francis CK: Predisposing factors for severe, uncontrolled hypertension in an inner-city minority population. N Engl J Med 1992, 327:776-781.
17. Balazovjech I, Hnilica P Jr: Compliance with antihypertensive treatment in consultation rooms for hypertensive patients. J Human Hypertens 1993, 7:581-583.
18. Wijman CA, Beijer IS, van Dijk GW, et al.: Hypertensive encephalopathy: does not only occur at high blood pressure (in Dutch). Ned Tijdsch Geneeskunde 2002, 146:969-973.
19. Eguchi K, Kasahara K, Nagashima A, et al.: Two cases of malignant hypertension with reversible diffuse leukoencephalopathy exhibiting a reversible nocturnal blood pressure "riser" pattern. Hypertens Res Clin Exp 2002, 25:467-473.
20. Lip GY, Beevers M, Beevers DG: Malignant hypertension in young women is related to previous hypertension in pregnancy, not oral contraception. QJM 1997, 90:571-575.
21. Zarifis J, Lip GY, Leatherdale B, Beevers G: Malignant hypertension in association with primary hyperaldosteronism. Blood Press 1996, 5:250-254.
22. Oka K, Hayashi K, Nakazato T, et al.: Malignant hypertension in a patient with primary hyperaldosteronism with elevated active renin concentration. Intern Med 1997, 36:700-704.
23. Suzuki H, Asano K Eiro M, et al.: Recovery from renal failure in malignant hypertension associated with primary aldosteronism: effect of an ACE-inhibitor. QJM 2002, 95:128-130.
24. Blumenfeld JD, Laragh JH: Management of hypertensive crises: the scientific basis for treatment decisions. Am J Hypertens 2001, 14:1154-1167.
25. Nagai T, Imamura M, Misumi S, Mori M: Subclinical Cushing's disease accompanied by malignant hypertension and diabetes mellitus. Intern Med 2002, 41:566-570.
26. Guerrera C, Colivicchi F, Pola R, et al.: Acute abdominal symptoms in malignant hypertension: clinical presentation in five cases. Clin Exp Hypertens 2001, 23:461-469.
27. Fukase S, Suzuki M, Goto T, et al.: IgA nephropathy with malignant hypertension (in Japanese). Nippon Naika Gakkai Zasshi 2002, 91:2473-2475.
28. Edmunds E, Landray MJ, Li-Saw-Hee FL, et al.: Dyslipidaemia in patients with malignant-phase hypertension. QJM 2001, 94:327-332.
29. Lip GY, Edmunds E, Hee FL, et al.: A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension. Am J Hypertens 2001, 14:823-828.
30. Lip GY, Edmunds E, Nuttall SL, et al.: Oxidative stress in malignant and nonmalignant phase hypertension. J Hum Hypertens 2002, 16:333-336.
31. Kato J, Kitamura K, Matsui E, et al.: Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. Hypertens Res 1999, 22:61-65.
32. Isles CG, McLay A, Boulton Jones JM: Recovery in malignant hypertension presenting as acute renal failure. QJM 1984, 53:439-458.
33. Bakir AA, Bazilinski N, Dunea G: Transient and sustained recovery from renal shutdown in accelerated hypertension. Am J Med 1986, 80:172-176.
34. Katz IJ, Sofianou L, Butler O, Hopley M: Recovery of renal function in Black South African patients with malignant hypertension: superiority of continuous ambulatory peritoneal dialysis over hemodialysis. Perit Dial Int 2001, 21:581-586.
35. Browning AC, Mengher LS, Gregson RM, Amoaku WM: Visual outcome of malignant hypertension in young people. Arch Dis Child 2001, 85:401-403.
36. Brott T, Bogousslavsky J: Drug therapy: treatment of acute ischemic stroke. N Engl J Med 2000, 343:710-722.
37. Grossman E, Ironi AN, Messerli FH: Comparative tolerability profile of hypertensive crisis treatments. Drug Safety 1998, 19:99-122.
38. Grossman E, Messerli. FH, Grodzicki T, Kowey P: Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996, 276:1328-1331.
39. Winker MA: The FDA's decisions regarding new indications for approved drugs. Where's the evidence? [editorial]. JAMA 1996, 276:1342-1343.
40. Murphy MB, Murray C, Shorten GD: Fenoldopam: a selective peripheral dopamine-receptor agonist for treatment of severe hypertension. N Engl J Med 2001, 345:1548-1557.
41. Shusterman NH, Elliott WJ, White WB: Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with normal or impaired baseline renal function. Am J Med 1993, 95:161-168.
42. Tumlin JA, Dunbar LM, Oparil S, et al.: Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial. Fenoldopam Study Group. Acad Emerg Med 2000, 7:653-662.
43. Piltz JR, Stone RA, Boike S, et al.: Fenoldopam, a selective dopamine-1 receptor agonist, raises intraocular pressure in males with normal intraocular pressure. J Ocul Pharmacol Ther 1998, 14:203-216.
44. Copper ZA, Mihm FG: Blood pressure control with fenoldopam during excision of a pheochromocytoma. Anesthesiology 1999, 91:558-560.
45. Strauser LM, Pruitt RD, Tobias JD: Initial experience with fenoldopam in children. Am J Ther 1999, 6:283-288.
46. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000, 183:S1-S22.
47. Tumlin JA, Wang A, Murray PT, Mathur VS: Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention ofcontrast nephropathy. Am Heart J 2002, 143:894-903.
48. Gilbert TB, Hasnain JU, Flinn WR, et al.: Fenoldopam infusion associated with preserving renal function after aortic cross-clamping for aneurysm repair. J Cardiovasc Pharmacol Ther 2001, 6:31-36.
49. Halpenny M, Lakshmi S, O'Donnell A, et al.: The effects of fenoldopam on coronary conduit blood flow after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2001, 15:72-76.
50. Halpenny M, Rushe C, Breen P, et al.: The effects of fenoldopam on renal function in patients undergoing electiv aortic surgery. Eur J Anaesthesiol 2002, 19:32-39.